Clinical Improvement
VENTAVIS® (iloprost) Inhalation Solution is a synthetic analogue of prostacyclin (PGI2).1 It dilates systemic and pulmonary arterial vascular beds. It also affects platelet aggregation, although the relevance of this effect to the treatment of pulmonary arterial hypertension is unknown.1
Established efficacy in both Functional Class III and Functional Class IV patients1
6MWD in functional class III patients1
6MWD in functional class IV patients1
In clinical studies, VENTAVIS has been shown to help with the following1,4:
- Significant improvement in a combined endpoint of clinical improvement—improvement in functional class, 10% or greater increase in individual walk distance, and lack of clinical deterioration or death (p=0.0033)1
- Significant improvement in exercise capacity (p<0.01)1
- Significant improvement in New York Heart Association (NYHA) Functional Class (p=0.03)4,14
- Significant hemodynamic improvement for 3 key parameters (PVR, CO, and mPAP) (p<0.001)1,4
- 32% decrease in PVR†
- 18% increase in CO†
- 9% decrease in mPAP†
- 3% increase (p=NS) in SVO2 from baseline at week 12 postinhalation
- The relationship between hemodynamic changes and clinical effects is unknown
- †Placebo-corrected.
AIR Pivotal Trial: Randomized, double-blind, multicenter, placebo-controlled trial to evaluate the efficacy and safety of VENTAVIS monotherapy compared with placebo in the treatment of PAH (WHO Group 1) NYHA Functional Class III or IV (n=146). Clinical improvement is a combined endpoint defined as ≥10% increase in 6MWD, improvement in NYHA Functional Class, and absence of clinical deterioration or death.1,4
Hemodynamics assessed at Week 12 before inhalation in both groups (at least 2 hours after previous dose, trough) and after inhalation in the VENTAVIS group (approximately 15 minutes after dose, peak). Study included patients with chronic thromboembolic disease (CTEPH) and all etiologies of PAH.1
For more information, please see full Prescribing Information.